AstraZeneca PLC (AZNCF)
| Previous close | 0.00 |
| Open | 169.00 |
| Bid | 149.09 x 40700 |
| Ask | 160.66 x 36900 |
| Day's range | 166.00 - 169.00 |
| 52-week range | 118.16 - 175.00 |
| Volume | |
| Avg. volume | 2,045 |
| Market cap | 246.024B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 37.05 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.98 (1.95%) |
| Ex-dividend date | 08 Aug 2024 |
| 1y target est | N/A |
- Business Wire
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
WILMINGTON, Del., October 07, 2024--Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca’s AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.1 The trial included patients with intermittent or mild persistent asthma, including those on short-acting
- Business Wire
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del., October 03, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
WILMINGTON, Del., October 01, 2024--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting based on positive results from the DESTI
